AIM ImmunoTech Statistics
Share Statistics
AIM ImmunoTech has 68.75M
shares outstanding. The number of shares has increased by 26.52%
in one year.
| Shares Outstanding | 68.75M |
| Shares Change (YoY) | 26.52% |
| Shares Change (QoQ) | 13.34% |
| Owned by Institutions (%) | 8.06% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,317 |
| FTD / Avg. Volume | 0.21% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.64 and the forward
PE ratio is null.
AIM ImmunoTech's PEG ratio is
0.01.
| PE Ratio | -0.64 |
| Forward PE | n/a |
| PS Ratio | 65.24 |
| Forward PS | 0.1 |
| PB Ratio | -8.39 |
| P/FCF Ratio | -0.74 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for AIM ImmunoTech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.44,
with a Debt / Equity ratio of -2.22.
| Current Ratio | 0.44 |
| Quick Ratio | 0.44 |
| Debt / Equity | -2.22 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.2 |
| Interest Coverage | -33.8 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $8,095.24 |
| Profits Per Employee | $-824,761.9 |
| Employee Count | 21 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -79.07% in the
last 52 weeks. The beta is 0.76, so AIM ImmunoTech's
price volatility has been higher than the market average.
| Beta | 0.76 |
| 52-Week Price Change | -79.07% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 0.23 |
| Relative Strength Index (RSI) | 23.34 |
| Average Volume (20 Days) | 1,121,082 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of 170K
and earned -17.32M
in profits. Earnings per share was -0.31.
| Revenue | 170K |
| Gross Profit | 139K |
| Operating Income | -19.77M |
| Net Income | -17.32M |
| EBITDA | -16.49M |
| EBIT | -16.73M |
| Earnings Per Share (EPS) | -0.31 |
Full Income StatementBalance Sheet
The company has 1.7M in cash and 2.94M in
debt, giving a net cash position of -1.24M.
| Cash & Cash Equivalents | 1.7M |
| Total Debt | 2.94M |
| Net Cash | -1.24M |
| Retained Earnings | n/a |
| Total Assets | 8.61M |
| Working Capital | -5.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -14.89M
and capital expenditures -18K, giving a free cash flow of -14.91M.
| Operating Cash Flow | -14.89M |
| Capital Expenditures | -18K |
| Free Cash Flow | -14.91M |
| FCF Per Share | -0.27 |
Full Cash Flow StatementMargins
Gross margin is 81.76%, with operating and profit margins of -11630.59% and -10188.24%.
| Gross Margin | 81.76% |
| Operating Margin | -11630.59% |
| Pretax Margin | -10188.24% |
| Profit Margin | -10188.24% |
| EBITDA Margin | -9699.41% |
| EBIT Margin | -11630.59% |
| FCF Margin | -8768.24% |
